Evidence map›Paper›PMID 29683207›Full record

ArticleGlia2018

The wmN1 enhancer region in intron 1 is required for expression of human PLP1.

Hamdan Hamdan, Pankaj Patyal, Neriman T Kockara, Patricia A Wight

Abstract read
In one paragraph

Article in Glia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Detection of a complex chromosomal rearrangement in a novel mouse mutant by optical genome mapping.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  2. Review
  3. Article
  4. Frontiers in cellular neuroscience · 2023
    Article
  5. Frontiers in cellular neuroscience · 2022
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hamdan HamdanDepartment of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Pankaj PatyalDepartment of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Neriman T KockaraDepartment of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Patricia A WightDepartment of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.ORCID 0000-0003-3841-6143

Funding

Arkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0M
ANTISILENCING OF PLP GENE EXPRESSION IN OLIGODENDROCYTESR01NS037821 · NINDS · UNIV OF ARKANSAS FOR MED SCIS · PI WIGHT, PATRICIA A. · 1998 to 2010
$2.0M
Multiple Sclerosis Society RG2705NCATS NIH HHS UL1 TR000039NCATS NIH HHS UL1TR000039NINDS NIH HHS R01 NS037821NINDS NIH HHS R01NS037821
6 · The paper itself

Abstract

The myelin proteolipid protein gene (PLP1) encodes the most abundant protein present in myelin from the central nervous system (CNS). Its expression must be tightly controlled as evidenced by mutations that alter PLP1 dosage; both overexpression (elevated PLP1 copy number) and lack thereof (PLP1 deletion) result in X-linked genetic disorders in man. However, not much is known about the mechanisms that govern expression of the human gene. To address this, transgenic mice were generated which utilize human PLP1 (hPLP1) sequences (proximal 6.2 kb of 5'-flanking DNA to the first 38 bp of exon 2) to drive expression of a lacZ reporter cassette. LoxP sites were incorporated around a 1.5-kb section of hPLP1 intron 1 since it contains sequence orthologous to the wmN1 region from mouse which, previously, was shown to augment expression of a minimally-promoted transgene coincident with the active myelination period of CNS development. Eight transgenic lines were generated with the parental, 6.2hPLP(+)Z/FL, transgene. All lines expressed the transgene appropriately in brain as evidenced by staining with X-gal in white matter regions and olfactory bulb. Removal of the "wmN1" region from 6.2hPLP(+)Z/FL with a ubiquitously expressed Cre-driver caused a dramatic reduction in transgene activity. These results demonstrate for the first time that the wmN1 enhancer region: (1) is functional in hPLP1; (2) works in collaboration with its native promoter-not just a basal heterologous promoter; (3) is required for high levels of hPLP1 gene activity; (4) has a broader effect, both spatially and temporally, than originally projected with mPlp1.

Indexed as

AnimalsBrainHumansMice, TransgenicMyelin Proteolipid ProteinMyelin SheathOligodendrogliaPromoter Regions, GeneticTransfectionTransgenesMyelin Proteolipid ProteinPLP1 protein, humanCre/loxPgene regulationlacZmyelin proteolipid protein genetransgenic mouse

Identifiers

PMID29683207
PMCPMC6201313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.